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the beginning of a whole new phase of 
studies.”
Mediawatch: Nigel Williams looks at the reaction to the first report of gene 
therapy impacting on human sight problems.
Eye catching“Scientists for the first time have 
used gene therapy to dramatically 
improve sight in people with a rare 
form of blindness, a development 
that experts called a major advance 
for the experimental technique,” said 
the Gainsville Sun in Florida, the state 
in which the results were announced 
at a meeting last month. It’s a story 
that excited many news editors with a 
number of angles to heighten reader 
or audience interest.
From London’s Independent, which 
splashed the story across its front 
page, the impression was that of a 
British achievement. “Experts hailed 
the research, supported by £1 million 
from the Department of Health, as 
a major advance in the treatment of 
blindness and predicted it would lead 
to new developments in gene therapy 
for other conditions,” the paper said.
It went on to quote Dawn Primarolo, 
the Public Health minister: “This is a 
major achievement for British science 
and the NHS (National Health Service) 
and shows that we truly are at the 
forefront of innovation.”
But, as the Gainsville Sun and 
other newspapers pointed out, British 
researchers were only part of the 
story. Some vision was restored in 
four of the six young people who got 
the treatment, three in the US and 
three in the UK. Two of the volunteers 
who could only see hand motions 
were able to read a few lines of an 
eye chart within weeks. While the 
Independent excitedly reported 
the visual improvements in one of 
the British patients, it’s rival, the 
Guardian, pointed out on its front 
page, in a tag for its science page 
report on the work many pages later, 
that the other two British patients 
showed no effect.
But other papers, like the 
Independent, were more upbeat. “It’s 
a phenomenal breakthrough,” said 
Stephen Rose, chief research officer 
of the Foundation Fighting Blindness, 
which helped pay for one study 
carried out at the Children’s Hospital 
of Philadelphia, in a widely used 
quote.If successful in large numbers, 
experts said, the technique has the 
potential to reverse blindness from 
other kinds of inherited eye diseases.
Many reports then looked at the 
potential in these results. “I think 
this is incredibly exciting,” said Jean 
Bennett, a professor of ophthalmology 
at the University of Pennsylvania and 
a leader of the Philadelphia study. “It’s 
The research was published online 
by the New England Journal of 
Medicine alongside the presentations 
at the meeting in Florida.
The two teams of scientists, 
working separately, each tested gene 
replacement therapy in three patients 
with a form of rare hereditary eye 
disease called Leber’s congenital 
amaurosis. There is no treatment 
for the disease, which appears in 
Full on: London’s Independent devoted its front page to the story of gene therapy improving 
the sight of one young British man.
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East Africa’s iconic lesser flamingo 
is widely distributed around the 
Rift Valley lakes, but it breeds 
almost exclusively at only one 
site: Lake Natron in Tanzania. So 
conservationists are bothered 
about plans to develop a plant to 
extract soda ash from the lake which 
threatens to disturb the breeding 
birds at this most remote site.
Lake Natron Resources Limited, 
a company jointly owned by the 
government of Tanzania and TATA 
Chemicals of Mumbai, India, proposes 
to develop a facility at Lake Natron to 
extract and process soda ash.
To nest successfully, lesser 
flamingos require very specific 
conditions. Lake Natron, but no other 
site, provides these.
“The proposed plant poses major 
risks to the lesser flamingos from 
disturbance, including increased 
populations of nest predators, and 
changes to the water balance and 
chemistry of the lake,” says Chris 
Magin, of the UK’s Royal Society for 
the Protection of Birds (RSPB), one of 
the organisations spearheading the 
case against the new plant.
Soda ash mining also threatens 
the tourism industry throughout East 
Africa and the livelihoods of the local 
people who depend on the lake basin.
Conservationists are fighting to 
protect the key breeding site of East 
Africa’s iconic lesser flamingos. Nigel 
Williams reports.
Soda battles
Threatened: Although widely dispersed and numerous at East African lakes, almost all lesser 
flamingos breed at Lake Natron in Tanzania, where plans for a new soda plant are causing con-
cern for conservationists, locals and tourist organisers. (Photo: David Tipling/Alamy.)infancy and causes severe vision loss, 
especially at night.
An estimated 2,000 Americans have 
the form of the disease they targeted, 
Bennett said. But other reports 
were not satisfied with a mere 2,000 
potential beneficiaries. New hope is 
offered to “millions affected by eye 
diseases” said the Independent. This 
was “hundreds of thousands” in the 
Los Angeles Times.
But the LA Times also highlighted 
the chequered history of gene 
therapy. It has been a “snakebitten 
field”, it reported. Gene therapy has 
been studied in humans for over 15 
years with limited success. The field 
suffered a setback in 1999 with the 
death of Jesse Geslinger, aged 18, in 
an experiment for a liver disorder. And 
some children treated for an immune 
disorder later developed leukaemia, 
many papers reported.
However, the early results of the 
eye experiments should give the 
field a boost, many reporters said. 
For the experiment, the scientists 
injected copies of a working gene 
beneath the retina. Only one eye 
was treated in each patient — the 
worst one — in case anything went 
wrong; the untreated eye was used for 
comparison. After the treatment, the 
patient’s eyesight and light sensitivity 
were measured periodically; mobility 
was tested in a maze or an obstacle 
course. All three of those treated 
in Philadelphia “reported improved 
vision in the injected eyes,” said the 
LA Times. 
The vector used to get the genes 
into the cells was developed by 
Katherine High, in Philadelphia for that 
team’s trial, whereas the British team 
used a vector created by Targeted 
Genetics Corp of Seattle.
No surprise then, that Washington 
States’ Seattle Times flagged up the 
local interest. “The research, some 
of which involves Seattle biotech 
Targeted Genetics, marks a major 
milestone for gene therapy.”
In the British group, the treatment 
only worked in Steven Howarth, 
aged 18, whose disease was less 
advanced than the other two. So 
perhaps the strongest British story 
ran in the Manchester Evening News. 
Howarth lives in Bolton, just outside 
Manchester. “A Bolton teenager has 
benefited from breakthrough gene 
therapy,” the newspaper trumpeted, 
bringing both the science and local 
interest angles to the fore.
